A real approved drug
Tesamorelin (brand name Egrifta) is a synthetic version of growth-hormone-releasing hormone — it nudges your own pituitary to make more growth hormone, rather than injecting growth hormone directly.
In 2010 it became FDA-approved for one specific use: reducing excess abdominal fat in people with HIV-associated lipodystrophy. That approval puts it in rare company among peptides.
What the trials found
Across two 26-week Phase 3 trials, tesamorelin significantly reduced visceral adipose tissue — the deep fat packed around the organs — and trimmed waist circumference, while barely touching the subcutaneous fat under the skin. The benefit held through 52 weeks of continued treatment.
Side effects were mostly injection-site reactions and the usual growth-hormone-related effects, like joint aches and mild swelling.
The fine print
Two honest limits the reviews stress. First, the strong evidence is in a specific population — HIV-associated lipodystrophy — so general "belly fat" use rests on much thinner data. Second, when treatment stopped, the visceral fat came back.
One of the few peptides with genuine FDA approval and Phase 3 data behind a specific claim — shrinking visceral fat. Outside that exact use, you're extrapolating beyond what was actually tested.